SIRPA and neoplasm: reported that the injection of bone marrow-derived macrophages pretreated with SIRPα blocking antibody exhibited intratumoral accumulation and phagocytotic activity for 1-2 weeks in mouse model, although these macrophages quickly differentiated toward nonphagocytic TAM phenotype and lost tumor-suppressive activity (153).